MUMBAI : MUMBAI: Dragging on Sun Pharmaceutical's otherwise decent Q4 results was the impact of cost increases.
While the pharmaceutical major's specialty business has picked up, a further squeeze on margins may dampen investor sentiment for the stock in coming quarters.
The stock was up 1.8% at ₹458.50 per share in trade on Thursday. One key parameter that the Street was looking out for was the ramp-up in its specialty division.
Ilumya, among its key branded formulation products, logged sales of about $94 million in FY20, higher than estimates and therefore quite encouraging.